Metyrapone as Additive Treatment in Major Depression

Phase 2 Completed 63 enrolled University Medical Center Hamburg-Eppendorf

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test whether metyrapone is an effective and safe augmenting agent in the treatment of major depression.

Timeline

Start: 1998-05
Primary completion: —
Completion: 2001-07

Outcome

Met primary endpoint

paper day 21 (23 of 33 patients) and at day 35 (19 of 33 patients) compared with placebo patients PMID 15583115 ↗

paper day 21: 13 of 30 patients; Fisher exact P = .031; day 35: 10 of 30 patients; Fisher exact P = .047). PMID 15583115 ↗

paper The clinical course of patients treated with metyrapone showed an earlier onset of action (Kaplan-Meier analysis; log-rank test P<.006) PMID 15583115 ↗

Publications

Results Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004 Dec;61(12):1235-44. doi: 10.1001/archpsyc.61.12.1235.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metyrapone	Small molecule	1 g	—